Tango Therapeutics, Inc. (TNGX) Return on equity 2020–2025
Tango Therapeutics, Inc. (TNGX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-29.3%FY2025 · since FY2020: -134.6% → -29.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -29.3% | +36.0 pp |
| FY2024 | -65.3% | -25.1 pp |
| FY2023 | -40.2% | +3.2 pp |
| FY2022 | -43.4% | -26.5 pp |
| FY2021 | -16.9% | +117.8 pp |
| FY2020 | -134.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice